Arteris Revenue Jumps, But Widening Losses Raise Concerns

Ticker: AIP · Form: 10-Q · Filed: 2025-11-04T00:00:00.000Z

Sentiment: bearish

Topics: Semiconductor IP, Networks-on-Chip, Financial Performance, Operating Expenses, Net Loss, Stockholders' Deficit, Revenue Growth

TL;DR

**Arteris is burning cash faster than it's growing, making it a risky bet despite strong revenue numbers.**

AI Summary

Arteris, Inc. (AIP) reported a significant increase in total revenue for both the three and nine months ended September 30, 2025. Total revenue for the three months increased by 18.3% to $17.408 million from $14.713 million in the prior year, driven by a 17.7% rise in licensing, support, and maintenance revenue to $15.896 million and a 25.4% increase in variable royalties to $1.512 million. For the nine months, total revenue grew by 19.4% to $50.442 million from $42.235 million. Despite this revenue growth, the company's net loss widened to $8.991 million for the three months, up from $7.687 million, and to $26.242 million for the nine months, compared to $25.434 million in the prior year. This increased loss was primarily due to a substantial rise in operating expenses, with research and development up 6.1% to $12.648 million and sales and marketing up 38.0% to $6.850 million for the three months. The company's stockholders' deficit deepened to $11.449 million as of September 30, 2025, from a deficit of $1.188 million at December 31, 2024, indicating a deteriorating financial position. Cash and cash equivalents increased to $17.417 million from $13.684 million, partly due to net cash provided by operating activities of $3.563 million for the nine months.

Why It Matters

Arteris's strong revenue growth, particularly in licensing and royalties, signals robust demand for its Networks-on-Chip (NoC) interconnect IP, which is crucial in the competitive semiconductor design market. However, the escalating net losses and deepening stockholders' deficit are red flags for investors, indicating that increased operational costs are outpacing revenue gains. This could impact the company's ability to fund future innovation and compete with larger players. Employees might face uncertainty if profitability doesn't improve, while customers could benefit from continued product development, assuming the company can sustain its operations. The broader market will watch if AIP can translate its sales momentum into sustainable profitability, a key challenge for many high-growth tech firms.

Risk Assessment

Risk Level: high — The company reported a net loss of $8.991 million for the three months ended September 30, 2025, and a cumulative net loss of $26.242 million for the nine months, exacerbating its accumulated deficit to $163.127 million. Furthermore, the stockholders' deficit significantly worsened to $11.449 million as of September 30, 2025, from $1.188 million at December 31, 2024, indicating a precarious financial position and potential liquidity challenges.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to AIP. The widening net losses and deepening stockholders' deficit suggest a challenging path to profitability, despite revenue growth. Monitor future filings closely for any signs of cost control or a clear strategy to reverse the negative equity trend.

Financial Highlights

debt To Equity
N/A
revenue
$17,408,000
operating Margin
-49.9%
total Assets
$107,737,000
total Debt
$119,186,000
net Income
-$8,991,000
eps
N/A
gross Margin
90.0%
cash Position
$17,417,000
revenue Growth
+18.3%

Revenue Breakdown

SegmentRevenueGrowth
Licensing, support and maintenance$15,896,000+17.7%
Variable royalties and other$1,512,000+25.4%

Key Numbers

Key Players & Entities

FAQ

What were Arteris, Inc.'s total revenues for the three and nine months ended September 30, 2025?

Arteris, Inc.'s total revenue for the three months ended September 30, 2025, was $17.408 million, an increase from $14.713 million in the same period of 2024. For the nine months ended September 30, 2025, total revenue reached $50.442 million, up from $42.235 million in the prior year.

How did Arteris's net loss change in the third quarter of 2025?

Arteris's net loss for the three months ended September 30, 2025, was $8.991 million, which is a worsening from the $7.687 million net loss reported for the same period in 2024.

What is Arteris, Inc.'s current stockholders' deficit?

As of September 30, 2025, Arteris, Inc. reported a total stockholders' deficit of $11.449 million. This represents a significant increase from the $1.188 million deficit recorded at December 31, 2024.

What were the key drivers of increased operating expenses for Arteris in Q3 2025?

Key drivers of increased operating expenses for Arteris in Q3 2025 included a 6.1% rise in research and development to $12.648 million and a substantial 38.0% increase in sales and marketing expenses to $6.850 million, compared to the same period in 2024.

How much cash did Arteris generate from operating activities in the first nine months of 2025?

Arteris generated $3.563 million in net cash from operating activities for the nine months ended September 30, 2025. This is an improvement from the $1.911 million generated in the corresponding period of 2024.

What is the significance of Arteris's deepening stockholders' deficit for investors?

The deepening stockholders' deficit to $11.449 million indicates that the company's liabilities exceed its assets, signaling a precarious financial position. For investors, this suggests increased financial risk and potential challenges in securing future funding or achieving long-term profitability.

Does Arteris, Inc. have any major customers that account for a significant portion of its revenue?

Yes, Customer A accounted for 13% of Arteris, Inc.'s total revenue for both the three and nine months ended September 30, 2025, and 15% for the same periods in 2024.

What are Arteris's non-cancelable contracted but unsatisfied performance obligations?

As of September 30, 2025, Arteris had $101.1 million in non-cancelable contracted but unsatisfied or partially satisfied performance obligations. The company expects to recognize $50.1 million of this balance over the next 12 months.

What is Arteris's business model?

Arteris, Inc. develops, licenses, and supports on-chip interconnect fabric technology used in System-on-Chip (SoC) designs and Networks-on-Chip (NoC) interconnect intellectual property (IP). They also provide software, support, professional services, and training for efficient deployment of their NoC IP.

What new accounting pronouncements is Arteris evaluating?

Arteris is evaluating the impact of ASU 2025-06 (Targeted Improvements to the Accounting for Internal-Use Software), ASU 2025-05 (Financial Instruments - Credit Losses), and ASU 2024-03/2025-01 (Disaggregation of Income Statement Expenses) on its consolidated financial statements and disclosures.

Risk Factors

Industry Context

Arteris operates in the semiconductor intellectual property (IP) market, a critical but highly competitive segment of the technology industry. The demand for its IP is tied to the growth and innovation cycles of the semiconductor industry, particularly in areas like AI, automotive, and high-performance computing. Key trends include the increasing complexity of chip designs and the need for specialized IP solutions to accelerate time-to-market.

Regulatory Implications

Arteris must navigate complex international trade regulations, including export controls and sanctions, which can impact its global sales and supply chain operations. Compliance with these regulations is crucial to avoid penalties and maintain market access.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Stockholders' Deficit
A situation where a company's total liabilities exceed the total value of its assets, resulting in a negative equity position for shareholders. (Indicates a deteriorating financial position for Arteris, Inc., with liabilities exceeding assets by $11.449 million as of September 30, 2025.)
Deferred Revenue
Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. It is recorded as a liability on the balance sheet. (Arteris has significant deferred revenue ($46.243M current, $39.629M noncurrent), representing future revenue streams but also obligations to customers.)
Unsatisfied Performance Obligations
Represents the total value of future revenue that the company is contractually obligated to recognize from existing contracts. (The $101.1M figure indicates substantial future revenue commitments, but also the scale of work required to fulfill these obligations.)
Accumulated Deficit
The cumulative net losses of a company since its inception, minus any cumulative net profits. (Arteris has an accumulated deficit of $163.127 million as of September 30, 2025, reflecting its history of net losses.)
Operating Lease Right-of-Use Assets
An asset recognized by a lessee under a lease, representing the right to use an underlying asset for the lease term. (Arteris has $4.195 million in operating lease ROU assets, reflecting its commitments for leased property and equipment.)

Year-Over-Year Comparison

Compared to the prior year, Arteris has demonstrated robust revenue growth, with total revenue increasing by 18.3% to $17.408 million for Q3 2025 and by 19.4% to $50.442 million for the nine months ended September 30, 2025. However, this top-line growth has been overshadowed by a widening net loss, which increased from $7.687 million to $8.991 million in Q3 and from $25.434 million to $26.242 million for the nine months. Operating expenses, particularly sales and marketing (up 38.0%), have risen significantly. A key concern is the deepening stockholders' deficit, which grew from $1.188 million at the end of 2024 to $11.449 million as of September 30, 2025, indicating a worsening financial position despite revenue gains.

Filing Stats: 4,610 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2025-11-04 17:06:20

Key Financial Figures

Filing Documents

Financial Information

Part I. Financial Information 3 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' (Deficit) Equity for the Three and N ine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 35 Item 4.

Controls and Procedures

Controls and Procedures 35

Other Information

Part II. Other Information 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 73 Item 3. Defaults Upon Senior Securities 74 Item 4. Mine Safety Disclosures 74 Item 5. Other Information 74 Item 6. Exhibits 75

Signatures

Signatures 76 2 Table of Contents

- Financial Information

Part I - Financial Information

Financial Statements

Item 1. Financial Statements Arteris, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) As of September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 17,417 $ 13,684 Short-term investments (Note 5) 21,567 30,157 Accounts receivable, net of allowance of $ 123 and $ 131 as of September 30, 2025 and December 31, 2024, respectively 16,480 20,608 Prepaid expenses and other current assets 5,566 4,634 Total current assets 61,030 69,083 Property and equipment, net 4,461 4,019 Long-term investments (Note 5) 17,237 8,504 Equity method investment 3,723 5,802 Operating lease right-of-use assets 4,195 3,838 Intangibles, net 2,361 3,024 Goodwill 4,178 4,178 Other assets 10,552 7,687 TOTAL ASSETS $ 107,737 $ 106,135 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $ 517 $ 539 Accrued expenses and other current liabilities 17,212 15,899 Operating lease liabilities, current 1,186 917 Deferred revenue, current 46,243 40,445 Vendor financing arrangements, current 1,614 1,482 Total current liabilities 66,772 59,282 Deferred revenue, noncurrent 39,629 35,177 Operating lease liabilities, noncurrent 3,431 2,998 Vendor financing arrangements, noncurrent 624 594 Deferred income, noncurrent 6,749 7,631 Other liabilities 1,981 1,641 Total liabilities 119,186 107,323 Commitments and contingencies (Note 10) Stockholders' deficit: Preferred stock, par value of $ 0.001 - 10,000,000 shares authorized and no shares issued and outstanding as of both September 30, 2025 and December 31, 2024 — — Common stock, par value of $ 0.001 - 300,000,000 shares authorized as of both September 30, 2025 and December 31, 2024; 43,584,272 and 40,724,936 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 43 40 Additional paid-in capital 151,377 135,522 Accumulated other comprehensive income 258 135 Accumulated deficit

View on Read The Filing